You might like
MajesTEC-3 ASH LBA Best result ever in a RRMM randomized trial. It will transform how we approach myeloma. Congratulations to authors and @JNJNews meetings-api.hematology.org/api/abstract/v…
With almost 1,000 myeloma-related communications at this @ASH_hematology #ASH25, it is now impossible to come up with a “Top 10 abstracts” list. Here are 10 topics I found interesting and speak to the continued progress in the #mmsm field on bright display this year
Happy to share our experience in managing #MGRS in @BrJHaem. #PGNMID remains an area for improvement. Excellent work by Daniel Cancilla and our coauthors. @Bethfaiman @FaizAnwerMD1 @khouri_jack @jamecancerdoc @CleClinicMD #mmsm onlinelibrary.wiley.com/doi/10.1111/bj…
A new contribution from MRC myeloma XI showing that with good diagnostic testing functional high risk is very rare @MyMKaiser
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia nature.com/articles/s4137… What are your thoughts?
👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL
A lot in #mmsm at ASCO. JNJ-5322 is likely the greatest innovation we have seen in a few years. Potential to disrupt our approach to immunotherapy even before we figure out the current players. @JNJInnovMed congratulations to the investigators meetings.asco.org/abstracts-pres…
It will be an interesting discussion but looking at more of those details provided by the briefing , it is becoming clear that there is no clear benefit of early treatment for smoldering myeloma based on what we know #mmsm My recommendedariob will remain to observe all patients…
Answers to a more and more common problem in patients with Waldenstrom's Macroglobulinemia; what to do when progressing on or intolerant of a BTK inhibitor? read our latest publication: doi.org/10.1053/j.semi…
🚨New milestone for #CARTcell therapy in #GlobalHematology! We report the first successful decentralized, academic-grade CD19 CAR-T manufacturing in healthy donors in Mexico 🇲🇽 and half a dream come true. 📄 JCO Global Oncology: ascopubs.org/doi/10.1200/GO… 1/🧵👇
“Bad habits we need to quit” in CML, per @DrHKantarjian @ #ThinkTank25 If you want o hear more, watch the video… it’s gold! @drsangeetmd @CarrawayHetty
Results from our Phase III ECHO trial of acalabrutinib + BR vs placebo + BR in untreated MCL patients ≥ 65-y.o. showed PFS was substantially improved in the acalabrutinib arm (66.4 vs 49.6 mo., p = 0.016). Toxicity in both arms was manageable. tinyurl.com/ECHO-ABR
Among patients with negative day 46 MRD, those who also had negative MRD at day 19 have particularly favorable treatment outcomes. ow.ly/z1MK50VHuzH #lymphoidneoplasia #clincialtrialsandobservation #pediatrichematology
#Hematology Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial - @TheLancetHaem #lymsm thelancet.com/journals/lanha…
Antalet vårdplatser i svensk sjukvård är betydligt färre än i andra europeiska länder. Vill påminna om det utmärkta förslag som IVO:s tidigare generaldirektör Sofia Wallström lade fram för ett par år sedan, om krav på ett minsta antal. (Statistik nedan ur SvD igår.)
Extended-dose DOAC vs full-dose DOAC #Renove RCT #ASH24 Late breaking abstract. Officially, reduced dose was not non-inferior, but recurrent #VTE rates were low and there is a substantial reduction in major and non-major bleeding. Congrats to @FCouturaud & @INNOVTE1
CONGRESS | #ASH24 | PRESENTATION Marie José Kersten @Kersten_MJ @amsterdamumc highlights results from the ongoing phase I/II ATALANTA-1 trial. GLPG5101 CAR T-cell therapy demonstrated promising efficacy, with CR rates of 100%, 95%, and 54% in patients with R/R MCL, R/R FL/MZL,…
Lots of great #mmsm science to be presented at #ASH24 – here to share some abstracts I’ll be paying special attention to in multiple myeloma with a focus on potential changes to the future care of patients.
1/ #ASH24 Choosing my top 10 myeloma abstracts this year was harder than ever!! Kudos to all @ASH_hematology authors for GREAT work 👏 For simplicity, I excluded investigational drugs and focused on: 1️⃣ #MMsm response assessments 2️⃣ Optimizing bsAbs 3️⃣ (Soon) practice-changing
United States Trends
- 1. Black Friday 393K posts
- 2. Egg Bowl 4,355 posts
- 3. Mississippi State 2,753 posts
- 4. Kamario Taylor N/A
- 5. Emmett Johnson N/A
- 6. #SkylineSweeps N/A
- 7. NextNRG Inc 1,793 posts
- 8. Scott Stricklin N/A
- 9. Wetjen N/A
- 10. Trinidad Chambliss N/A
- 11. Solo Ball N/A
- 12. #Rashmer 24K posts
- 13. #FanCashDropPromotion 1,777 posts
- 14. #Huskers N/A
- 15. Kewan Lacy N/A
- 16. Sumrall 1,136 posts
- 17. Black Ops 7 XP 2,027 posts
- 18. #jonita 19.9K posts
- 19. Fisch 1,069 posts
- 20. WHO DEY 12.3K posts
Something went wrong.
Something went wrong.